Thomas Sarazin

Mr. Thomas Sarazin

CNRS UMR 7369 – Extracellular Matrix and Cellular Dynamics (MEDyC), Department of Biology, University of Reims Champagne-Ardenne.

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2019 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
AWAmandine Wahart
Amandine Wahart
THThinhinane Hocine
Thinhinane Hocine
CACamille Albrecht
Camille Albrecht
AHAuberi Henry
Auberi Henry
TSThomas Sarazin
Thomas Sarazin
LDLaurent Duca
Laurent Duca
The Cardiovascular Continuum describes a sequence of events from cardiovascular risk factors to end‐stage heart disease. It includes conventional pathologies affecting cardiovascular functions such as hypertension, atherosclerosis or thrombosis and was traditionally considered from the metabolic point of view. This Cardiovascular Continuum, originally described by Dzau and Braunwald, was extended by O'Rourke to consider also the crucial role played by degradation of elastic fibers, occurring during aging, in the appearance of vascular stiffness, another deleterious risk factor of the continuum. However, the involvement of the elastin degradation products, named elastin‐derived peptides, to the Cardiovascular Continuum progression has not been considered before. Data from our laboratory and others clearly showed that these bioactive peptides are central regulators of this continuum, thereby amplifying appearance and evolution of cardiovascular risk factors such as diabetes or hypertension, of vascular alterations such as atherothrombosis and calcification, but also nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. The Elastin Receptor Complex has been shown to be a crucial actor in these processes. We propose here the participation of these elastin‐derived peptides and of the Elastin Receptor Complex in these events, and introduce a revisited Cardiovascular Continuum based on their involvement, for which elastin‐based pharmacological strategies could have a strong impact in the future.

1 December 2017 in Phytochemistry
Verified
Journal Article
Closed access
MLMeryem Lehbili
Meryem Lehbili
AMAbdulmagid ALABDUL MAGID
Abdulmagid ALABDUL MAGID
AKAhmed Kabouche
Ahmed Kabouche
LVLaurence Voutquenne-Nazabadioko
Laurence Voutquenne-Nazabadioko
AAAmin Abedini
Amin Abedini
ZKZahia Kabouche
Zahia Kabouche

7 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
AJAlbin JEANNE
Albin JEANNE
TSThomas Sarazin
Thomas Sarazin
MCMagalie Charlé
Magalie Charlé
CMCatherine Moali
Catherine Moali
CFCaroline Fichel
Caroline Fichel
Stephane DedieuStephane Dedieu
Stephane Dedieu
TAX2 peptide is a cyclic peptide that acts as an orthosteric antagonist for thrombospondin-1 (TSP-1) interaction with CD47. TAX2 was first described for its anti-angiogenic activities and showed anti-cancer efficacy in numerous preclinical models. Here, we aimed at providing an extensive molecular characterization of TAX2 mode of action, while evaluating its potential in ovarian cancer therapy. Multidisciplinary approaches were used to qualify a TAX2 drug candidate in terms of stability, solubility and potency. Then, efficacy studies, together with benchmark experiments, were performed in relevant mouse models of ovarian carcinoma. TAX2 peptide appears to be stable and soluble in clinically relevant solvents, while displaying a favorable safety profile. Moreover, clinical data mining allowed for the identification of TSP-1 as a relevant pharmacological target in ovarian cancer. In mice, TAX2 therapy inhibits ovarian tumor growth and metastatic dissemination, while activating anti-cancer adaptive immunity. Interestingly, TAX2 also synergizes when administered in combination with anti-PD-1 immune checkpoint inhibitiors. Altogether, our data expose TAX2 as an optimized candidate with advanced preclinical characterization. Using relevant syngeneic ovarian carcinoma models, we highlighted TAX2’s ability to convert poorly immunogenic tumors into ones displaying effective anti-tumor T-cell immunity.

1 January 2021 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
AJAlbin Jeanne
Albin Jeanne
TSThomas Sarazin
Thomas Sarazin
MCMagalie Charlé
Magalie Charlé
CKCharlotte Kawecki
Charlotte Kawecki
AKAlexandre Kauskot
Alexandre Kauskot
Stephane DedieuStephane Dedieu
Stephane Dedieu
Objective: TSP-1 (thrombospondin 1) is one of the most expressed proteins in platelet α-granules and plays an important role in the regulation of hemostasis and thrombosis. Interaction of released TSP-1 with CD47 membrane receptor has been shown to regulate major events leading to thrombus formation, such as, platelet adhesion to vascular endothelium, nitric oxide/cGMP (cyclic guanosine monophosphate) signaling, platelet activation as well as aggregation. Therefore, targeting TSP-1:CD47 axis may represent a promising antithrombotic strategy. Approach and Results: A CD47-derived cyclic peptide was engineered, namely TAX2, that targets TSP-1 and selectively prevents TSP-1:CD47 interaction. Here, we demonstrate for the first time that TAX2 peptide strongly decreases platelet aggregation and interaction with collagen under arterial shear conditions. TAX2 also delays time for complete thrombotic occlusion in 2 mouse models of arterial thrombosis following chemical injury, while Thbs1 −/− mice recapitulate TAX2 effects. Importantly, TAX2 administration is not associated with increased bleeding risk or modification of hematologic parameters. Conclusions: Overall, this study sheds light on the major contribution of TSP-1:CD47 interaction in platelet activation and thrombus formation while putting forward TAX2 as an innovative antithrombotic agent with high added-value.

6 April 2026
Verified
Thesis
Closed access
TSThomas Sarazin
Thomas Sarazin
La TSP-1 est l’une des protéines les plus exprimées dans les granules α des plaquettes et joue un rôle important dans la régulation de la thrombose. L’interaction de la TSP-1 sécrétée avec le récepteur membranaire CD47 régule des événements majeurs conduisant à la formation du thrombus, tels que l’adhérence à l’endothélium vasculaire, l’activation, la signalisation ainsi que l’agrégation plaquettaire.Dans cette thèse, nous démontrons qu’un peptide cyclique dérivé de CD47, nommé TAX2, antagoniste orthostérique de l’interaction TSP-1:CD47, diminue significativement l’agrégation plaquettaire induite par différents agonistes dans des échantillons biologiques humains de complexité croissante. TAX2 inhibe également l’interaction des plaquettes avec le collagène dans des conditions de cisaillement artériel. In vivo, TAX2 retarde le temps d’occlusion thrombotique totale dans deux modèles murins de thrombose artérielle chimio-induite, et récapitule les effets anti-thrombotiques observés chez les souris Thbs1−/−. De manière importante, l’administration aiguë ou chronique de TAX2 est sûre et n’est pas associée à un risque accru de saignement ni à une modification des paramètres de la coagulation.Les plaquettes jouent, par ailleurs, un rôle primordial lors de l’établissement des foyers métastatiques d’origine hématogène qui nécessitent l’arrêt, la fixation et l’extravasation des cellules tumorales. Dans la lignée des découvertes récentes démontrant l’efficacité des médicaments anti-thrombotiques actuels en tant qu’agents anti-tumoraux, nos résultats démontrent la capacité de TAX2 à diminuer la taille des hétéro-agrégats de plaquettes et de cellules cancéreuses de mélanome B16F10, ainsi que le nombre de cellules cancéreuses par agrégats. TAX2 réduit également de manière significative la potentialisation par les plaquettes des capacités d’adhérence, de migration, de migration trans-endothéliale et d’invasion des cellules B16F10.